Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Profit After Tax (2023 - 2025)

CG Oncology's Profit After Tax history spans 3 years, with the latest figure at -$41.3 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 29.87% year-over-year to -$41.3 million; the TTM value through Dec 2025 reached -$161.0 million, down 82.85%, while the annual FY2025 figure was -$161.0 million, 82.87% down from the prior year.
  • Profit After Tax reached -$41.3 million in Q4 2025 per CGON's latest filing, up from -$43.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$8.7 million in Q1 2023 to a low of -$43.8 million in Q3 2025.
  • Average Profit After Tax over 3 years is -$24.8 million, with a median of -$19.7 million recorded in 2024.
  • The largest YoY upside for Profit After Tax was 29.87% in 2025 against a maximum downside of 119.16% in 2025.
  • A 3-year view of Profit After Tax shows it stood at -$16.6 million in 2023, then crashed by 92.07% to -$31.8 million in 2024, then fell by 29.87% to -$41.3 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Profit After Tax are -$41.3 million (Q4 2025), -$43.8 million (Q3 2025), and -$41.4 million (Q2 2025).